Overview

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This phase Ⅱ study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Yuhong Li
Treatments:
Fluorouracil
Irinotecan
Leucovorin